NN6.F NANOREPRO AG

Healthcare Biotechnology Frankfurt Exchange
1.39 EUR
Close of Nov 12, 2026
1.31 2.26
Market cap
EUR 17.5M
P/E
-
P/B
0.47x
ROE
-5.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is NN6.F undervalued?

Graham number

The Graham number of NANOREPRO AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NANOREPRO AG fundamental analysis

No fundamental analysis for NANOREPRO AG yet.

NANOREPRO AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NANOREPRO AG

NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company offers products in the areas of family planning, preventive healthcare, intolerances, and infectious diseases. It also develops and commercializes immunochromatographic lateral flow tests; and point of care testing for hospitals and medical practices. NanoRepro AG was incorporated in 20…

Full company profile